Tandem Diabetes Care
TNDM
Tandem Diabetes Care (TNDM) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Barclays | Initiated Coverage | Equal-Weight | $18.00 | Oct 7, 2026 |
| Citigroup | Maintained | Neutral | $20.00 from $24.00 | Sep 30, 2026 |
| Truist Securities | Maintained | Buy | $28.00 from $31.00 | Sep 24, 2026 |
| William Blair | Initiated Coverage | Outperform | — | Aug 21, 2026 |
| RBC Capital | Maintained | Outperform | $26.00 from $30.00 | Aug 7, 2026 |
| Citigroup | Maintained | Neutral | $21.00 from $17.00 | Aug 7, 2026 |
| UBS | Initiated Coverage | Neutral | $18.00 from $22.00 | Jul 28, 2026 |
| Mizuho | Maintained | Neutral | $20.00 from $24.00 | Jul 15, 2026 |
| Deutsche Bank | Initiated Coverage | Buy → Hold | $15.50 | Jun 23, 2026 |
| Wells Fargo | Upgraded | Equal-Weight → Overweight | $27.00 from $21.00 | Jun 1, 2026 |
| Citigroup | Maintained | Neutral | $17.00 from $22.00 | May 28, 2026 |
| B of A Securities | Maintained | Neutral | $25.00 from $35.00 | May 18, 2026 |
| Benchmark | Initiated Coverage | Hold | — | May 12, 2026 |
| Barclays | Maintained | Overweight | $55.00 from $56.00 | May 11, 2026 |
| Truist Securities | Maintained | Buy | $31.00 from $35.00 | May 11, 2026 |
| TD Cowen | Maintained | Buy | $28.00 from $25.00 | Apr 20, 2026 |
| Goldman Sachs | Maintained | Neutral | $25.00 from $28.00 | Apr 9, 2026 |
| Truist Securities | Upgraded | Hold → Buy | $35.00 from $27.00 | Mar 19, 2026 |
| Piper Sandler | Upgraded | Neutral → Overweight | $33.00 from $21.00 | Mar 17, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $25.00 from $23.00 | Mar 2, 2026 |
Frequently asked questions
What is the latest analyst rating on TNDM?
On Oct 7, 2026, Barclays initiated coverage of Tandem Diabetes Care at Equal-Weight with a price target of $18.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.